#postexposure — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #postexposure, aggregated by home.social.
-
New HIV prevention guidelines say doctors should not be ‘gatekeeping’ medications
A coalition of doctors across Canada is releasing a new guideline for prescribing medications that can prevent HIV…
#NewsBeep #News #Health #CA #Canada #HIVpreventionguidelines #HIVprophylaxis #postexposure #pre-exposure
https://www.newsbeep.com/ca/319153/ -
Oral #Nirmatrelvir–Ritonavir as #Postexposure #Prophylaxis for #Covid19, N Engl J Med.: https://www.nejm.org/doi/full/10.1056/NEJMoa2309002
In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir–ritonavir for 5 or 10 days did not significantly reduce the #risk of symptomatic #SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.)
-
Oral #Nirmatrelvir–Ritonavir as #Postexposure #Prophylaxis for #Covid19, N Engl J Med.: https://www.nejm.org/doi/full/10.1056/NEJMoa2309002
In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir–ritonavir for 5 or 10 days did not significantly reduce the #risk of symptomatic #SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.)
-
Oral #Nirmatrelvir–Ritonavir as #Postexposure #Prophylaxis for #Covid19, N Engl J Med.: https://www.nejm.org/doi/full/10.1056/NEJMoa2309002
In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir–ritonavir for 5 or 10 days did not significantly reduce the #risk of symptomatic #SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.)
-
Oral #Nirmatrelvir–Ritonavir as #Postexposure #Prophylaxis for #Covid19, N Engl J Med.: https://www.nejm.org/doi/full/10.1056/NEJMoa2309002
In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir–ritonavir for 5 or 10 days did not significantly reduce the #risk of symptomatic #SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.)
-
Oral #Nirmatrelvir–Ritonavir as #Postexposure #Prophylaxis for #Covid19, N Engl J Med.: https://www.nejm.org/doi/full/10.1056/NEJMoa2309002
In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir–ritonavir for 5 or 10 days did not significantly reduce the #risk of symptomatic #SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.)